Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cardillo

Showing results (31-40 of 132) with videos related to

Pageof 14
Sort By:
European Journal of Histochemistry : EJH|January 1, 1997
Comparison of four methods for CD34+ cell enumeration in cord bloodL Porretti, G Puglisi, P Rebulla, et al.
Blood|April 18, 2009
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphomaEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Clinical Transplants|August 22, 2001
Kidney transplantation in the north Italy transplant programM Cardillo, M Scalamogna, C Pizzi, et al.
Blood|August 28, 2009
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomasEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Plos One|May 23, 2013
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cellsDonglin Liu, Chien-Hsing Chang, Edmund A Rossi, et al.
Transplantation Proceedings|August 10, 2010
C4d-positive renal allograft rejection biopsies in cyclosporine-treated patients: single-center incidence and outcomeM Valente, L Furian, F Marchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugatesSerengulam V Govindan, Thomas M Cardillo, Sung-Ju Moon, et al.
Molecular Cancer Therapeutics|July 24, 2014
Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-αEdmund A Rossi, Diane L Rossi, Thomas M Cardillo, et al.
Mabs|February 5, 2014
A new class of bispecific antibodies to redirect T cells for cancer immunotherapyDiane L Rossi, Edmund A Rossi, Thomas M Cardillo, et al.
Molecular Cancer Therapeutics|October 3, 2022
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug ReleaseAnna Kopp, Scott Hofsess, Thomas M Cardillo, et al.
Pageof 14

Showing results (31-40 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Histochemistry : EJH|January 1, 1997
Comparison of four methods for CD34+ cell enumeration in cord bloodL Porretti, G Puglisi, P Rebulla, et al.
Blood|April 18, 2009
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphomaEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Clinical Transplants|August 22, 2001
Kidney transplantation in the north Italy transplant programM Cardillo, M Scalamogna, C Pizzi, et al.
Blood|August 28, 2009
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomasEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Plos One|May 23, 2013
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cellsDonglin Liu, Chien-Hsing Chang, Edmund A Rossi, et al.
Transplantation Proceedings|August 10, 2010
C4d-positive renal allograft rejection biopsies in cyclosporine-treated patients: single-center incidence and outcomeM Valente, L Furian, F Marchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugatesSerengulam V Govindan, Thomas M Cardillo, Sung-Ju Moon, et al.
Molecular Cancer Therapeutics|July 24, 2014
Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-αEdmund A Rossi, Diane L Rossi, Thomas M Cardillo, et al.
Mabs|February 5, 2014
A new class of bispecific antibodies to redirect T cells for cancer immunotherapyDiane L Rossi, Edmund A Rossi, Thomas M Cardillo, et al.
Molecular Cancer Therapeutics|October 3, 2022
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug ReleaseAnna Kopp, Scott Hofsess, Thomas M Cardillo, et al.
Pageof 14